Ninety-day post-operative morbidity and mortality using the National Cancer Institute’s common terminology criteria for adverse events better describe post-operative outcome after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

References

• Sadeghi B, Arvieux C, Glehen O, et al. (2000). Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88:358–63.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH, Cunliffe WJ, Belliveau J, et al. (1989). Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol 16(4 Suppl 6):83–97.
   Web of Science ®Google Scholar
• Gilly FN, Sayag AC, Carry PY, et al. (1991). Intra-peritoneal chemo-hyperthermia (CHIP): a new therapy in the treatment of the peritoneal seedings. Preliminary report. Int Surg 76:164–7.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Stewart JH, Shen P, et al. (2014). Outcomes with cytoreductive surgery and HIPEC for peritoneal metastasis. J Surg Oncol 110:575–84.
   PubMed Web of Science ®Google Scholar
• Vaira M, Robella M, Mellano A, et al. (2014). Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence. Int J Hyperthermia 30:565–9.
   PubMed Web of Science ®Google Scholar
• Tan G, Chia C, Kumar M, et al. (2017). 201 consecutive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in a single Asian tertiary centre. Int J Hyperthermia 33:288–94.
   PubMed Web of Science ®Google Scholar
• Chua TC, Yan TD, Saxena A, Morris DL. (2009). Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg 249:900–7.
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, van Tinteren H, Ruth SV, Zoetmulder FA. (2004). Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 85:61–7.
   PubMed Web of Science ®Google Scholar
• Smeenk RM, Verwaal VJ, Zoetmulder FA. (2006). Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei–a report of 103 procedures. Eur J Surg Oncol 32:186–90.
   PubMed Web of Science ®Google Scholar
• Passot G, Vaudoyer D, Villeneuve L, et al. (2016). What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1,125 procedures. J Surg Oncol 113:796–803.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common Terminology Criteria for Adverse Events v.3.0and v.4.0 (CTCAE). Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm [last accessed 14 Jun 2011].
   Google Scholar
• Dindo D, Demartines N, Clavien PA. (2004). Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–13.
   PubMed Web of Science ®Google Scholar
• Mise Y, Vauthey JN, Zimmitti G, et al. (2015). Ninety-day postoperative mortality is a legitimate measure of hepatopancreatobiliary surgical quality. Ann Surg 262:1071–8.
   PubMed Web of Science ®Google Scholar
• Schwarz L, Bruno M, Parker NH, et al. (2015). Active surveillance for adverse events within 90 days: the standard for reporting surgical outcomes after pancreatectomy. Ann Surg Oncol 22:3522–9.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. (1995). Peritonectomy procedures. Ann Surg 221:29–42.
   PubMed Web of Science ®Google Scholar
• Kim BJ, Caudle AS, Gottumukkala V, Aloia TA. (2016). The impact of postoperative complications on a timely return to intended oncologic therapy (RIOT): the role of enhanced recovery in the cancer journey. Int Anesthesiol Clin 54:e33–46.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events v3.0 (CTCAE). Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. [last accessed 10 Jun 2013].
   Google Scholar
• Trotti A, Colevas AD, Setser A, et al. (2003). CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–81.
   PubMed Web of Science ®Google Scholar
• Lehmann K, Eshmuminov D, Slankamenac K, et al. (2016). Where oncologic and surgical complication scoring systems collide: time for a new consensus for CRS/HIPEC. World J Surg 40:1075–81.
   PubMed Web of Science ®Google Scholar
• Younan R, Kusamura S, Baratti D, et al. (2008). Morbidity, toxicity, and mortality classification systems in the local regional treatment of peritoneal surface malignancy. J Surg Oncol 98:253–7.
   PubMed Web of Science ®Google Scholar
• Simkens GA, van Oudheusden TR, Luyer MD, et al. (2015). Serious postoperative complications affect early recurrence after cytoreductive surgery and HIPEC for colorectal peritoneal carcinomatosis. Ann Surg Oncol 22:2656–62.
   PubMed Web of Science ®Google Scholar
• Baratti D, Kusamura S, Iusco D, et al. (2014). Postoperative complications after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy affect long-term outcome of patients with peritoneal metastases from colorectal cancer: a two-center study of 101 patients. Dis Colon Rectum 57:858–68.
   PubMed Web of Science ®Google Scholar
• Goere D, Malka D, Tzanis D, et al. (2013). Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg 257:1065–71.
   PubMed Web of Science ®Google Scholar
• Kaibori M, Iwamoto Y, Ishizaki M, et al. (2012). Predictors and outcome of early recurrence after resection of hepatic metastases from colorectal cancer. Langenbeck’s Arch Surg 397:373–81.
   PubMed Web of Science ®Google Scholar
• Law WL, Choi HK, Lee YM, Ho JW. (2007). The impact of postoperative complications on long-term outcomes following curative resection for colorectal cancer. Ann Surg Oncol 14:2559–66.
   PubMed Web of Science ®Google Scholar
• Mirnezami A, Mirnezami R, Chandrakumaran K, et al. (2011). Increased local recurrence and reduced survival from colorectal cancer following anastomotic leak: systematic review and meta-analysis. Ann Surg 253:890–9.
   PubMed Web of Science ®Google Scholar
• Halkia E, Kopanakis N, Nikolaou G, Spiliotis J. (2015). Cytoreductive surgery and HIPEC for peritoneal carcinomatosis. A review on morbidity and mortality. J BUON 20:S80–S7.
   PubMedGoogle Scholar
• Khuri SF, Daley J, Henderson W, et al. (1998). The Department of Veterans Affairs’ NSQIP: the first national, validated, outcome-based, risk-adjusted, and peer-controlled program for the measurement and enhancement of the quality of surgical care. National VA Surgical Quality Improvement Program. Ann Surg 228:491–507.
   PubMed Web of Science ®Google Scholar
• Damhuis RA, Wijnhoven BP, Plaisier PW, et al. (2012). Comparison of 30-day, 90-day and in-hospital postoperative mortality for eight different cancer types. Br J Surg 99:1149–54.
   PubMed Web of Science ®Google Scholar
• Russell EM, Bruce J, Krukowski ZH. (2003). Systematic review of the quality of surgical mortality monitoring. Br J Surg 90:527–32.
   PubMed Web of Science ®Google Scholar
• Simkens GA, van Oudheusden TR, Braam HJ, et al. (2016). Treatment-related mortality after cytoreductive surgery and HIPEC in patients with colorectal peritoneal carcinomatosis is underestimated by conventional parameters. Ann Surg Oncol 23:99–105.
   PubMed Web of Science ®Google Scholar
• Tabrizian P, Shrager B, Jibara G, et al. (2014). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. J Gastrointest Surg 18:1024–31.
   PubMed Web of Science ®Google Scholar
• Mise Y, Day RW, Vauthey JN, et al. (2016). After pancreatectomy, the “90 days from surgery” definition is superior to the “30 days from discharge” definition for capture of clinically relevant readmissions. J Gastrointest Surg 20:77–84. discussion
   PubMed Web of Science ®Google Scholar
• Swanson RS, Pezzi CM, Mallin K, et al. (2014). The 90-day mortality after pancreatectomy for cancer is double the 30-day mortality: more than 20,000 resections from the national cancer data base. Ann Surg Oncol 21:4059–67.
   PubMed Web of Science ®Google Scholar